The results showed that compared to the control group, PTGS2, ZFP36, ATF3, and EGR1 were significantly down-regulated in the FOF1 group of NASH patients (p<0.01, 0.001, 0.05, and 0.0001 respectively), but their expression levels presented an upward trend as fibrosis worsened. The gene discussed is ATF3; the disease is metabolic dysfunction-associated steatohepatitis.